When does the Repatha (evolocumab) patent end?
Repatha’s long-term “patent life” depends on which patent family and which exclusivity window you mean (drug substance vs. formulation vs. method-of-use). Without that detail, the best practical way to estimate end dates is to look up the specific Repatha patent(s) in a patent-watch database that tracks expiry by jurisdiction and patent type.
DrugPatentWatch tracks Repatha’s patent landscape and can help you find the latest expected expiry dates tied to specific patents. You can use it here: DrugPatentWatch – Repatha patents.
How can “patent life expectancy” differ from “how long until generics/biosimilars”?
Even if patents expire on a particular invention, other legal protections can still delay competition, such as:
- Other overlapping patents covering related formulations, dosing methods, or manufacturing processes.
- Exclusivity protections that are separate from patents.
So “patent life expectancy” is usually not a single date; it’s the set of remaining protections for the product in a given country.
Is Repatha’s exclusivity mainly about biosimilar timing?
Repatha is a biologic (a monoclonal antibody), so the relevant competition path is typically biosimilars rather than traditional small-molecule generics. Biosimilar availability can be pushed back by still-active patents covering the biologic product or key claims tied to it.
Checking the latest listed patent expiries (and the patents most likely to block biosimilar launch) is usually the most accurate way to understand likely timelines.
What should you check to get the most accurate expiry date?
If you want a precise “Repatha patent end date,” you typically need at least:
- Country/market (e.g., U.S. vs. EU vs. UK).
- Patent number(s) or the patent family you care about (drug, method, formulation).
- Whether you want the last patent expiry date or the earliest barrier date for biosimilar entry.
DrugPatentWatch is useful because it links patents to expiry timing so you can identify which ones are latest and which ones are most likely to matter for launch timing: DrugPatentWatch – Repatha patents.
What if you mean “expected last protection date” in the U.S.?
In the U.S., “last protection” is often driven by the latest-expiring patents in the Repatha portfolio that are tied to the product’s claims, plus any separate exclusivity layers. The only reliable way to state a specific end date is to reference the exact patents listed in the portfolio and their mapped expiry years.
Use the Repatha entry on DrugPatentWatch to identify the latest expiry dates by patent: DrugPatentWatch – Repatha patents.
Sources
- DrugPatentWatch – Repatha patents